Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q3 2019 · 10-Q
Revenue$682.00K$682.00K+10.5% vs Q3 2018 Net Income$4.07M$4.07MN/M vs Q3 2018 EPS Diluted$0.23$0.23−23.3% vs Q3 2018 Operating Income-$4,078,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,663,000N/M Margins · derivedOperating margin-597.9%+136.9 pt vs Q3 2018
Net margin597.1%+1302.7 pt vs Q3 2018
ended May 31, 2019 · filed Jul 10, 2019 · 40 d after period end